Lakefront Biotherapeutics (GLPGF) Current Assets (2013 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Current Assets for 14 consecutive years, with $3.6 billion the latest figure, recorded in Q1 2026.

• On a quarterly basis, Current Assets fell 1.89% year-over-year to $3.6 billion in Q1 2026; TTM through Mar 2026 was $3.6 billion, a 1.89% decrease from a year earlier, with the FY2025 full-year figure at $3.5 billion, down 3.74% from the prior year.
• Current Assets was $3.6 billion for Q1 2026 at Lakefront Biotherapeutics, roughly flat from $3.6 billion in the prior quarter.
• Over five years, Current Assets peaked at $4322.6 billion in Q4 2022 and troughed at $3.6 billion in Q4 2024.
• A 5-year average of $336.2 billion and a median of $3.9 billion in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets plunged 99.9% in 2023 and advanced 0.45% in 2025, its largest moves.
• Over 5 years, Current Assets stood at $4322.6 billion in 2022, then sank by 99.9% to $4.2 billion in 2023, then declined by 14.11% to $3.6 billion in 2024, then increased by 0.45% to $3.6 billion in 2025, then declined by 0.04% to $3.6 billion in 2026.
• The last three Current Assets figures came in at $3.6 billion (Q1 2026), $3.6 billion (Q4 2025), and $3.7 billion (Q3 2025), per Business Quant data.